Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: 181785-84-2, Beta-l-fd4c, L-fd4c, .beta.-l-fd4c, Ach-126,443, L-f-d4c
Molecular Formula
C9H10FN3O3
Molecular Weight
227.19  g/mol
InChI Key
HSBKFSPNDWWPSL-VDTYLAMSSA-N
FDA UNII
M09BUF90C0

Elvucitabine is a nucleoside reverse transcriptase inhibitor analog of cytosine. Elvucitabine has activity against HIV and chronic hepatitis B.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
2.1.2 InChI
InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1
2.1.3 InChI Key
HSBKFSPNDWWPSL-VDTYLAMSSA-N
2.1.4 Canonical SMILES
C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F
2.1.5 Isomeric SMILES
C1=C[C@H](O[C@H]1CO)N2C=C(C(=NC2=O)N)F
2.2 Other Identifiers
2.2.1 UNII
M09BUF90C0
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine

2. 2',3'-dideoxy-2',3'-didehydro-beta-d-5-fluorocytidine

3. 2',3'-dideoxy-2',3'-didehydro-beta-l-5-fluorocytidine

4. 2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-

5. 4-amino-5-fluoro-1-((2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1h)-one

6. Ach-126-443

7. Beta-d-d4fc

8. Beta-l-fd4c

9. D-d4fc

10. Dexelvucitabine

11. Dpc 817

12. Dpc-817

13. Dpc817

14. Incb-8721

15. L-d4fc

16. Reverset

2.3.2 Depositor-Supplied Synonyms

1. 181785-84-2

2. Beta-l-fd4c

3. L-fd4c

4. .beta.-l-fd4c

5. Ach-126,443

6. L-f-d4c

7. Ach-126443

8. L-d4fc

9. 4-amino-5-fluoro-1-((2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1h)-one

10. 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one

11. M09buf90c0

12. 2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-

13. 2(1h)-pyrimidinone, 4-amino-1-[(2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-fluoro-

14. Elvucitabine [usan]

15. Elvucitabine [usan:inn]

16. Unii-m09buf90c0

17. Ach 126443

18. Ach 126,443

19. B-l-fd4c

20. Elvucitabine (usan/inn)

21. Elvucitabine [inn]

22. Chembl38700

23. (-)fd4c

24. Schembl1649928

25. Zinc7048

26. Beta-l-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine

27. Dtxsid20171185

28. Bdbm50421604

29. Db06236

30. Hy-117582

31. Cs-0066557

32. A14435

33. D03981

34. J-011630

35. Q1334337

36. .beta.-l-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine

37. 2(1h)-pyrimidinone, 4-amino-1-(2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-, (2s-cis)-

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 227.19 g/mol
Molecular Formula C9H10FN3O3
XLogP3-1.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count2
Exact Mass227.07061935 g/mol
Monoisotopic Mass227.07061935 g/mol
Topological Polar Surface Area88.2 Ų
Heavy Atom Count16
Formal Charge0
Complexity405
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in hepatitis (viral, B) and HIV infection.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Reverse Transcriptase Inhibitors

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)


Anti-HIV Agents

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)


5.2 Mechanism of Action

Elvucitabine is a L-cytosine Nucleoside analog Reverse Transcriptase Inhibitor (NRTIs) anti-HIV drug. NRTI's inhibit the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body.